AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population

Coronary Artery Disease Clinical Trial

— ABSORB JAPAN  

Official title:

A Clinical Evaluation of AVJ-301 (Absorb™ BVS), the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Japanese Population

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01844284
• Other study ID #: 12-301
• Status: Completed
• Phase: N/A
• Start date: April 2013
• Est. completion date: January 16, 2019

Study information

• Verified date: July 2019
• Source: Abbott Medical Devices
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, Randomized (2:1), active control, single-blind, non-inferiority, multicenter, Japanese Clinical Trial to evaluate the safety and effectiveness of Absorb™ BVS (AVJ-301) in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions in Japanese population by comparing to approved metallic drug eluting stent.

Description:

Absorb™ BVS is currently in development at Abbott Vascular. Not available for sale in the US or Japan.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: January 16, 2019
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Subject must be at least 20 years of age.

2. Subject or a legally authorized representative must provide written Informed Consent prior to any study related procedure, per site requirements.

3. Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia) suitable for elective percutaneous coronary intervention (PCI).

4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery.

5. Subject must be able to take dual antiplatelet therapy for up to 1 year following the index procedure and anticoagulants prior/during the index procedure. Therefore the subject has no known allergic reaction, hypersensitivity or contraindication to aspirin, clopidogrel, ticlopidine or heparin.

6. Female subject of childbearing potential must not be pregnant* at the index procedure and does not plan pregnancy for up to 1 year following the index procedure.

• Except for non-pregnancy is apparent, negative pregnancy result within 7 days prior to the index procedure is required.

7. Female subject is not breast-feeding at the time of the screening visit and will not be breast-feeding for up to 1 year following the index procedure.

8. Subject agrees to not participate in any other investigational or invasive clinical study for a period of 13 months following the index procedure

Exclusion Criteria:

1. Elective surgery is planned within 1 year after the procedure that will require general anesthesia or discontinuing either aspirin or Thienopyridine.

2. Subject has known hypersensitivity or contraindication to device material and its degredants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated.

3. Subject has a known contrast sensitivity that cannot be adequately pre-medicated.

4. Subject had an acute myocardial infarction (AMI) within 72 hours of the index procedure

• The subject is currently experiencing clinical symptoms consistent with new onset AMI, such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes

• Creatine Kinase (CK) and Creatine Kinase - Muscle and Brain (CK-MB) have not returned to within normal limits at the time of index procedure.

5. Subject has an unstable cardiac arrhythmia which is likely to become hemodynamically unstable due to arrhythmia.

6. Subject has a known left ventricular ejection fraction (LVEF) < 30% (LVEF may be obtained at the time of the index procedure if the value is unknown and the investigator believes it is necessary).

7. The target vessel was treated by PCI within 12 months.

8. Prior PCI within the non-target vessel is acceptable if performed anytime > 30 days before the index procedure or between 24 hours and 30 days before the index procedure if successful and uncomplicated.

9. Subject requires future staged PCI either in target or non target vessels.

10. Subject has a malignancy that is not in remission.

11. Subject is receiving immunosuppressant therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.,). Note: corticosteroids are not included as immunosuppressant therapy, diabetes mellitus is not regarded as autoimmune disease.

12. Subject has received any solid organ transplants or is on a waiting list for any solid organ transplants.

13. Subject has previously received or scheduled to receive radiotherapy to coronary artery (brachytherapy), or chest/mediastinum.

14. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin or any other agent for any reason).

15. Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3.

16. Subject has a documented or suspected cirrhosis of Child-Pugh = Class B.

17. Subject has known renal insufficiency;

• Dialysis at the time of screening.

• An estimated Glomerular filtration rate (GFR) < 30 ml/min/1.73m2

18. Subject is high risk of bleeding, or difficult to have appropriate treatment;

• Has a history of bleeding diathesis or coagulopathy

• Has had a significant gastro-intestinal or significant urinary bleed within the past six months

• Has prior intracranial bleed

• Has prior intracranial bleed (including severe permanent neurologic deficit that seem to be caused by previous intracranial bleeding)

• Has known intracranial pathology that may cause intracranial bleeding per an investigator assessment (e.g. untreated aneurysm > 5 mm, arteriovenous malformation)

• Subject will refuse blood transfusions

19. Subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months,

20. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath insertion.

21. Subject has life expectancy < 3 year.

22. Subject is in the opinion of the Investigator or designee, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason.

23. Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.

24. Subject whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate (e.g. subordinate hospital staff or sponsor staff) or subject is unable to read or write.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Ischemia
• Myocardial Ischemia

Intervention

Device:
• XIENCE PRIME®/XIENCE Xpedition™
Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
• Absorb™ BVS
Subjects receiving Absorb™ BVS

Locations

Country	Name	City	State
Japan	Kansairosai Hospital	Amagasaki-shi	Hyogo
Japan	Juntendo University	Bunkyo-ku	Tokyo
Japan	University of Tokyo	Bunkyo-ku	Tokyo
Japan	Mitsui Memorial Museum	Chiyoda-ku	Tokyo
Japan	Sakakibara Memorial Hospital	Fuchu-shi	Tokyo
Japan	Tokai University	Isehara-shi	Kanagawa
Japan	Teikyo University	Itabashi-Ku	Tokyo
Japan	Shonankamakura General Hospital	Kamakura-shi	Kanagawa
Japan	Kanto Rosai Hospital	Kawasaki-shi	Kanagawa
Japan	Wakayama Medical University Hospital	Kimiidera	Wakayama
Japan	Kokura Memorial Hospital	Kitakyushu-shi	Fukuoka
Japan	Kobe University	Kobe-shi	Hyogo
Japan	Saiseikai Kumamoto Hospital	Kumamoto-shi	Kumamoto
Japan	Kurashiki Central Hospital	Kurashiki-shi	Okayama
Japan	Kurume University	Kurume-shi	Fukuoka
Japan	Shinkoga Hospital	Kurume-shi	Fukuoka
Japan	Kyoto University	Kyoto	Honshu
Japan	ShinTokyo	Matsudo-shi	Chiba
Japan	Toho University Ohashi Medical Center	Meguro-ku	Tokyo
Japan	The Cardiovascular Institute Hospital	Minato-Ku	Tokyo
Japan	Miyazak Medical Association Hospital	Miyazaki-shi	Miyazaki
Japan	Iwate Medical University	Morioka-shi	Iwate
Japan	Nagoya Daini Red Cross Hospital	Nagoya-shi	Aichi
Japan	Sakurabashi Watanabe Hospital	Osaka-shi	Osaka
Japan	Saitama Medical Center Jichi Medical University	Saitama-shi	Saitama
Japan	Hanaoka Seishu Memorial Cardiovascular Clinic	Sapporo-shi	Hokkaido
Japan	Saitama Sekishinkai	Sayama-shi	Saitama
Japan	Showa University Hospital	Shinagawa-ku	Tokyo
Japan	Tokyo Women's Medical University	Shinjuku-ku	Tokyo
Japan	Osaka University	Suita-shi	Osaka
Japan	The National Cerebral and Cardiovascular Center	Suita-shi	Osaka
Japan	Tenri Hospital	Tenri-shi	Nara
Japan	Dokkyo University	Tochigi	Utsunomiya
Japan	Tokushima Red Cross Hospital	Tokushima
Japan	Abbott Vascular Japan Co., Ltd.	Tokyo
Japan	Fujita Health University	Toyoake-shi	Aichi
Japan	Tsukuba Medical Center	Tsukuba-shi	Ibaraki
Japan	Yamaguchi University	Ube-shi	Yamaguchi
Japan	Saiseikai Yokohamashi Tobu Hospital	Yokohama-shi	Kanagawa

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Target Lesion Failure (TLF)	Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).	1 year
Secondary	Number of Participants With Any Death/Any MI/Revascularization (DMR)	DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization	= 7 days post index procedure (In-hospital )
Secondary	Number of Participants With Any Death/Any MI/Revascularization (DMR)	DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization	1 month
Secondary	Number of Participants With Any Death/Any MI/Revascularization (DMR)	DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization	6 months
Secondary	Number of Participants With Any Death/Any MI/Revascularization (DMR)	DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization	1 year
Secondary	Number of Participants With Any Death/Any MI/Revascularization (DMR)	DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization	2 years
Secondary	Number of Participants With Any Death/Any MI/Revascularization (DMR)	DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization	3 years
Secondary	Number of Participants With Any Death/Any MI/Revascularization (DMR)	DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization	4 years
Secondary	Number of Participants With Any Death/Any MI/Revascularization (DMR)	DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization	5 years
Secondary	Number of Participants With Target Vessel Failure (TVF)	Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).	= 7 days post index procedure (In-hospital )
Secondary	Number of Participants With Target Vessel Failure (TVF)	Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).	1 month
Secondary	Number of Participants With Target Vessel Failure (TVF)	Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).	6 months
Secondary	Number of Participants With Target Vessel Failure (TVF)	Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).	1 year
Secondary	Number of Participants With Target Vessel Failure (TVF)	Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).	2 years
Secondary	Number of Participants With Target Vessel Failure (TVF)	Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).	3 years
Secondary	Number of Participants With Target Vessel Failure (TVF)	Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).	4 years
Secondary	Number of Participants With Target Vessel Failure (TVF)	Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).	5 years
Secondary	Number of Participants With Target Lesion Failure (TLF)	Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).	= 7 days post index procedure (In-hospital )
Secondary	Number of Participants With Target Lesion Failure (TLF)	Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).	1 month
Secondary	Number of Participants With Target Lesion Failure (TLF)	Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).	6 months
Secondary	Number of Participants With Target Lesion Failure (TLF)	Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).	2 years
Secondary	Number of Participants With Target Lesion Failure (TLF)	Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).	3 years
Secondary	Number of Participants With Target Lesion Failure (TLF)	Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).	4 years
Secondary	Number of Participants With Target Lesion Failure (TLF)	Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).	5 years
Secondary	Number of Participants With Cardiac Death/All MI	Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves	= 7 days post index procedure (In-hospital )
Secondary	Number of Participants With Cardiac Death/All MI	Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves	1 month
Secondary	Number of Participants With Cardiac Death/All MI	Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves	6 months
Secondary	Number of Participants With Cardiac Death/All MI	Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves	1 year
Secondary	Number of Participants With Cardiac Death/All MI	Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves	2 years
Secondary	Number of Participants With Cardiac Death/All MI	Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves	3 years
Secondary	Number of Participants With Cardiac Death/All MI	Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves	4 years
Secondary	Number of Participants With Cardiac Death/All MI	Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.; Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves	5 years
Secondary	Number of Participants With All Target Vessel Revascularization (TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	= 7 days post index procedure (In-hospital )
Secondary	Number of Participants With All Target Vessel Revascularization (TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	1 month
Secondary	Number of Participants With All Target Vessel Revascularization (TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	6 months
Secondary	Number of Participants With All Target Vessel Revascularization (TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	1 year
Secondary	Number of Participants With All Target Vessel Revascularization (TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	2 years
Secondary	Number of Participants With All Target Vessel Revascularization (TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	3 years
Secondary	Number of Participants With All Target Vessel Revascularization (TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	4 years
Secondary	Number of Participants With All Target Vessel Revascularization (TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	5 years
Secondary	Number of Participants With Ischemia-driven TVR (ID-TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	= 7 days post index procedure (In-hospital )
Secondary	Number of Participants With Ischemia-driven TVR (ID-TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	1 month
Secondary	Number of Participants With Ischemia-driven TVR (ID-TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	6 months
Secondary	Number of Participants With Ischemia-driven TVR (ID-TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	1 year
Secondary	Number of Participants With Ischemia-driven TVR (ID-TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	2 years
Secondary	Number of Participants With Ischemia-driven TVR (ID-TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	3 years
Secondary	Number of Participants With Ischemia-driven TVR (ID-TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	4 years
Secondary	Number of Participants With Ischemia-driven TVR (ID-TVR)	Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.	5 years
Secondary	Number of Participants With All Target Lesion Revascularization (TLR)	Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.; The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.	= 7 days post index procedure (In-hospital )
Secondary	Number of Participants With All Target Lesion Revascularization (TLR)	Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.; The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.	1 month
Secondary	Number of Participants With All Target Lesion Revascularization (TLR)	Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.; The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.	6 months
Secondary	Number of Participants With All Target Lesion Revascularization (TLR)	Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.; The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.	1 year
Secondary	Number of Participants With All Target Lesion Revascularization (TLR)	Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.; The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.	2 years
Secondary	Number of Participants With All Target Lesion Revascularization (TLR)	Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.; The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.	3 years
Secondary	Number of Participants With All Target Lesion Revascularization (TLR)	Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.; The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.	4 years
Secondary	Number of Participants With All Target Lesion Revascularization (TLR)	Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.; The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.	5 years
Secondary	Number of Participants With Ischemia-driven Revascularization (ID-TLR)	A revascularization is considered ischemia-driven if associated with any of the following: Positive functional ischemia study including positive FFR; Ischemic symptoms and angiographic diameter stenosis = 50% by core laboratory QCA; Angiographic diameter stenosis = 70% by core laboratory QCA without angina or positive functional study	= 7 days post index procedure (In-hospital )
Secondary	Number of Participants With Ischemia-driven Revascularization (ID-TLR)	A revascularization is considered ischemia-driven if associated with any of the following: Positive functional ischemia study including positive FFR; Ischemic symptoms and angiographic diameter stenosis = 50% by core laboratory QCA; Angiographic diameter stenosis = 70% by core laboratory QCA without angina or positive functional study	1 month
Secondary	Number of Participants With Ischemia-driven Revascularization (ID-TLR)	A revascularization is considered ischemia-driven if associated with any of the following: Positive functional ischemia study including positive FFR; Ischemic symptoms and angiographic diameter stenosis = 50% by core laboratory QCA; Angiographic diameter stenosis = 70% by core laboratory QCA without angina or positive functional study	6 months
Secondary	Number of Participants With Ischemia-driven Revascularization (ID-TLR)	A revascularization is considered ischemia-driven if associated with any of the following: Positive functional ischemia study including positive FFR; Ischemic symptoms and angiographic diameter stenosis = 50% by core laboratory QCA; Angiographic diameter stenosis = 70% by core laboratory QCA without angina or positive functional study	1 year
Secondary	Number of Participants With Ischemia-driven Revascularization (ID-TLR)	A revascularization is considered ischemia-driven if associated with any of the following: Positive functional ischemia study including positive FFR; Ischemic symptoms and angiographic diameter stenosis = 50% by core laboratory QCA; Angiographic diameter stenosis = 70% by core laboratory QCA without angina or positive functional study	2 years
Secondary	Number of Participants With Ischemia-driven Revascularization (ID-TLR)	A revascularization is considered ischemia-driven if associated with any of the following: Positive functional ischemia study including positive FFR; Ischemic symptoms and angiographic diameter stenosis = 50% by core laboratory QCA; Angiographic diameter stenosis = 70% by core laboratory QCA without angina or positive functional study	3 years
Secondary	Number of Participants With Ischemia-driven Revascularization (ID-TLR)	A revascularization is considered ischemia-driven if associated with any of the following: Positive functional ischemia study including positive FFR; Ischemic symptoms and angiographic diameter stenosis = 50% by core laboratory QCA; Angiographic diameter stenosis = 70% by core laboratory QCA without angina or positive functional study	4 years
Secondary	Number of Participants With Ischemia-driven Revascularization (ID-TLR)	A revascularization is considered ischemia-driven if associated with any of the following: Positive functional ischemia study including positive FFR; Ischemic symptoms and angiographic diameter stenosis = 50% by core laboratory QCA; Angiographic diameter stenosis = 70% by core laboratory QCA without angina or positive functional study	5 years
Secondary	Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)	Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.; Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	= 7 days post index procedure (In-hospital )
Secondary	Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)	Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.; Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	1 month
Secondary	Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)	Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.; Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	6 months
Secondary	Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)	Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.; Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	1 year
Secondary	Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)	Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.; Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	2 years
Secondary	Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)	Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.; Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	3 years
Secondary	Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)	Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.; Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	4 years
Secondary	Number of Participants Experiencing All Death (Cardiac, Vascular, Non-Cardiovascular)	Cardiac Death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all study procedure related deaths including those related to concomitant treatment.; Vascular Death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.; Non-cardiovascular Death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.	5 years
Secondary	Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))	- Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	= 7 days post index procedure (In-hospital )
Secondary	Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))	- Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	1 month
Secondary	Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))	- Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	6 months
Secondary	Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))	- Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	1 year
Secondary	Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))	- Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	2 years
Secondary	Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))	- Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	3 years
Secondary	Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))	- Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	4 years
Secondary	Number of Participants With All Myocardial Infarction ((MI: Q-wave Myocardial Infarction (Q-MI) or Non- Q-wave Myocardial Infarction (NQ-MI))	- Q wave MI: Development of new, pathological Q wave on the ECG.; -Non-Q wave MI: Elevation of CK levels to = two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves.	5 years
Secondary	Number of Participants With Target Vessel MI (TV-MI)		= 7 days post index procedure (In-hospital )
Secondary	Number of Participants With Target Vessel MI (TV-MI)		1 month
Secondary	Number of Participants With Target Vessel MI (TV-MI)		6 months
Secondary	Number of Participants With Target Vessel MI (TV-MI)		1 year
Secondary	Number of Participants With Target Vessel MI (TV-MI)		2 years
Secondary	Number of Participants With Target Vessel MI (TV-MI)		3 years
Secondary	Number of Participants With Target Vessel MI (TV-MI)		4 years
Secondary	Number of Participants With Target Vessel MI (TV-MI)		5 years
Secondary	Number of Participants With Stent/Scaffold Thrombosis	ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.; Timings: Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: >1 year post stent implantation	Acute (= 1 day)
Secondary	Number of Participants With Stent/Scaffold Thrombosis	ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.; Timings: Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: >1 year post stent implantation	Subacute (>1 - 30 days)
Secondary	Number of Participants With Stent/Scaffold Thrombosis	ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.; Timings: Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: >1 year post stent implantation	Late (31 - 365 days)
Secondary	Number of Participants With Stent/Scaffold Thrombosis	ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.; Timings: Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: >1 year post stent implantation	Very Late (366 - 730 days)
Secondary	Number of Participants With Stent/Scaffold Thrombosis	ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.; Timings: Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: >1 year post stent implantation	Very Late (731 - 1095 days)
Secondary	Number of Participants With Stent/Scaffold Thrombosis	ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.; Timings: Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: >1 year post stent implantation	Very Late (1096 - 1460 days)
Secondary	Number of Participants With Stent/Scaffold Thrombosis	ITT population. Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.; Timings: Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation; Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation; Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation; Very late scaffold/stent thrombosis: >1 year post stent implantation	Very Late (1461 - 1825 days)
Secondary	In-segment Late Loss (Non-inferiority)		13 months
Secondary	Nitrate Vaso-reactivity Analysis / In-device Mean Lumen Diameter : Pre-Nitroglycerin (NTG)	Intracoronary nitrate injection was used for evaluating vaso-reactivity as it is routinely used during percutaneous coronary intervention (PCI) procedure.	2 years
Secondary	Nitrate Vaso-reactivity Analysis/ In-device Mean Lumen Diameter: Absolute Vaso Dilatation	Intracoronary nitrate injection was used for evaluating vaso-reactivity as it is routinely used during percutaneous coronary intervention (PCI) procedure.; Absolute Vaso dilatation = Post Nitroglycerin (NTG) - Pre Nitroglycerin (NTG)	2 years
Secondary	Nitrate Vaso-reactivity Analysis / In-device Mean Lumen Diameter : Post-Nitroglycerin (NTG)	Intracoronary nitrate injection was used for evaluating vaso-reactivity as it is routinely used during percutaneous coronary intervention (PCI) procedure.	2 years
Secondary	Number of Participants With Cardiac Death, All MI, ID-TLR (MACE)		5 years
Secondary	Number of Participants With Not Ischemia-driven TLR (NID-TLR)		5 years
Secondary	Number of Participants With Non-Target Vessel MI (NTV-MI)		5 years